Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.12 USD | +3.57% | +10.48% | -17.65% |
04-18 | Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing | MT |
04-16 | Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer | MT |
Sales 2024 * | 53.92M 73.7M | Sales 2025 * | 60.67M 82.93M | Capitalization | 1.93B 2.64B |
---|---|---|---|---|---|
Net income 2024 * | -411M -562M | Net income 2025 * | -481M -657M | EV / Sales 2024 * | 29.9 x |
Net cash position 2024 * | 322M 440M | Net cash position 2025 * | 279M 381M | EV / Sales 2025 * | 27.3 x |
P/E ratio 2024 * |
-4.78
x | P/E ratio 2025 * |
-4.33
x | Employees | 500 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.44% |
1 day | +3.57% | ||
1 week | +10.48% | ||
Current month | -18.56% | ||
1 month | -21.32% | ||
3 months | -16.97% | ||
6 months | +46.31% | ||
Current year | -17.65% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 41 | 13-11-04 | |
Blake Borgeson
FOU | Founder | 42 | 13-11-04 |
Dean Li
FOU | Founder | 62 | 13-11-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 20-03-19 |
Chairman | 60 | 20-03-31 | |
Dean Li
FOU | Founder | 62 | 13-11-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.51% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 8.12 | +3.57% | 4,394,004 |
24-04-25 | 7.84 | -1.26% | 4,382,391 |
24-04-24 | 7.94 | +3.12% | 7,206,016 |
24-04-23 | 7.7 | +1.32% | 5,111,318 |
24-04-22 | 7.6 | +3.40% | 3,946,342 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.65% | 1.93B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RXRX Stock